Fortune Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 18-07-2024
- Paid Up Capital ₹ 1.25 Cr
as on 18-07-2024
- Company Age 33 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.47 Cr
as on 18-07-2024
- Revenue %
(FY 2023)
- Profit 48.86%
(FY 2023)
- Ebitda 50.00%
(FY 2023)
- Net Worth
- Total Assets -24.48%
(FY 2023)
About Fortune Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.25 Cr.
The company currently has active open charges totaling ₹2.47 Cr.
Sohrab Gill, Abani Gill, and Jasjit Gill serve as directors at the Company.
- CIN/LLPIN
U24232PB1991PLC011297
- Company No.
011297
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Apr 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Moga, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Fortune Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jasjit Gill  | Managing Director | 02-Jul-2012 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sohrab Gill | Director | 07-May-2019 | Current |
| Abani Gill | Director | 31-May-2018 | Current |
Financial Performance and Corporate Structure Insights of Fortune Drugs.
Fortune Drugs Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 48.86% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fortune Drugs?
In 2022, Fortune Drugs had a public holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab State Ind. Development Corp. Ltd. Creation Date: 04 Dec 1996 | ₹5.00 M | Open |
Punjab State Ind. Development Corp. Ltd. Creation Date: 04 Dec 1996 | ₹1.00 Cr | Open |
Canara Bank Creation Date: 09 Feb 1994 | ₹1.20 M | Open |
How Many Employees Work at Fortune Drugs?
Unlock and access historical data on people associated with Fortune Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fortune Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fortune Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
